Tesamorelin: An Approved Pituitary Stimulator With a Narrow Indication

The short version

Tesamorelin is a synthetic version of the body's own growth hormone-releasing hormone (GHRH), the signal that tells the pituitary gland to release growth hormone. It has 44 amino acids — the same number as native GHRH — with a chemical modification at one end that prevents it from being broken down quickly in the bloodstream. It is the only peptide on this desk that has been approved as a medicine: the US FDA cleared it in 2010 specifically to reduce excess abdominal fat in HIV-infected adults whose antiretroviral therapy has redistributed fat to the belly ^[2].

Here is the important boundary. Controlled RCTs demonstrate real, measurable effects on visceral fat and liver fat in HIV patients ^[1][3][5][6]. Everything outside that indication — general fat reduction, anti-aging, cognitive enhancement in non-HIV populations — is off-label and investigational. Visceral fat returns when the drug is stopped ^[5]. It is prohibited in sport under WADA Section S2. This page summarizes what was studied; it is not advice and lists no human dose.

What it is

Tesamorelin acetate is a 44-amino-acid synthetic analogue of human growth hormone-releasing hormone (hGHRH(1-44)-NH2). The key modification is a trans-3-hexenoic acid group conjugated to the N-terminus (the starting end of the peptide chain). That modification confers resistance to dipeptidyl peptidase-IV (DPP-IV), an enzyme that would otherwise cleave and inactivate the peptide within minutes — so tesamorelin persists in circulation longer than native GHRH.

It is also known as TH9507, and in preclinical literature as a GHRH analogue or "growth hormone-releasing factor analogue." It is supplied as the acetate salt. Outside its approved indication, tesamorelin handled as a research chemical is not subject to the purity and potency oversight of the licensed pharmaceutical product ^[7].

How it works

Tesamorelin binds the growth hormone-releasing hormone receptor (GHRH-R) on anterior-pituitary somatotroph cells — the cells whose job is to make and release growth hormone. Binding activates a signalling cascade (Gs protein → adenylyl cyclase → cyclic AMP → protein kinase A) that triggers both GH synthesis and pulsatile GH secretion.

The released GH travels to the liver, where it stimulates production of insulin-like growth factor-1 (IGF-1). In a study of thirteen healthy men given tesamorelin at 2 mg/day for two weeks, overnight GH rose by a mean of 0.5 µg/L and IGF-1 increased by 181 µg/L — both statistically significant — while insulin sensitivity was not significantly affected ^[4].

The downstream effect on fat is specific: the GH produced by tesamorelin drives lipolysis preferentially in visceral adipose tissue (the fat stored around the abdominal organs). Because tesamorelin amplifies the body's own pulsatile GH rhythm rather than supplying exogenous GH, its metabolic profile differs from that of recombinant GH — an important distinction in clinical pharmacology ^[7].

What the research shows

Meta-analytic summary. A 2026 pooled analysis of five randomised controlled trials in HIV-associated lipodystrophy found that tesamorelin reduced visceral adipose tissue by a mean of 27.71 cm² (95% CI −38.37 to −17.06; P<0.001), trunk fat by 1.18 kg, and hepatic fat fraction by 4.28%, while increasing lean body mass by 1.42 kg — with no serious adverse events ^[1].

Pivotal Phase 3 RCT. In 412 HIV patients with abdominal fat accumulation, 26 weeks of tesamorelin at 2 mg/day reduced visceral adipose tissue by 15.2% while placebo increased it by 5.0%. Triglycerides fell by 50 mg/dL (versus +9 mg/dL with placebo) and IGF-1 rose by 81.0% ^[6].

JAMA hepatic fat RCT. In 50 antiretroviral-treated adults, the JAMA-published trial found a treatment effect of −42 cm² in visceral fat (P=0.005) and a net hepatic lipid reduction of −2.9% (P=0.003) at six months ^[3].

52-week durability. A long-term study (273 tesamorelin, 137 placebo) sustained an 18% reduction in visceral fat over 52 weeks (P<0.001 vs baseline); fat reaccumulated upon discontinuation, and glucose parameters over 52 weeks were not clinically significant ^[5].

GH pulsatility and liver safety. The NIH LiverTox monograph assigns tesamorelin likelihood score E — the lowest (most benign) category for drug-induced liver injury — noting no reported attributable liver-injury cases in trials ^[2]. The short-term healthy-men study confirmed that pulsatile GH secretion was preserved under GHRH-analogue stimulation and that insulin sensitivity was not significantly affected ^[4].

Reported effects, cautions and safety

Tesamorelin has the most extensive human safety dataset of the three peptides on this desk, but that dataset is specific to HIV patients, and several cautions are important:

• Indication boundary. FDA approval covers only HIV-associated lipodystrophy. All other uses — general visceral-fat reduction, anti-aging, cognitive enhancement, non-HIV fatty liver — are off-label and investigational. Generalizability to non-HIV populations is mechanistically plausible but unestablished by large RCTs ^[2].
• Rebound on discontinuation. Visceral fat reaccumulates within weeks of stopping tesamorelin; the benefit is contingent on continued dosing ^[5].
• GH/IGF-1 long-term safety. GH-axis stimulation raises serum IGF-1, a growth factor. Trials showed no excess malignancy signal over 52 weeks, but long-term oncologic-safety data are limited; active malignancy is a labelled contraindication ^[7].
• Glucose monitoring. Modest glucose perturbation can occur. Individuals with prediabetes or dysglycemia warrant monitoring, though the dedicated glucose trial found no significant HbA1c change ^[5].
• WADA prohibition. Tesamorelin is prohibited in sport under WADA Section S2 (peptide hormones, growth factors, related substances and mimetics), in- and out-of-competition ^[7].
• Research-grade supply. Outside the approved pharmaceutical product, research-grade tesamorelin lacks the purity and potency oversight of the licensed drug ^[7].

No community-anecdote reports are included in this desk's source material for tesamorelin, so none are presented; the above are drawn from the cited literature.

Where it fits in GH axis research

Among the three peptides on this desk, tesamorelin is the lead and the best-supported in human studies. Its controlled trial record in HIV lipodystrophy is the most rigorous data available for any GHRH analogue in humans — and that record is what makes its boundaries worth stating precisely. The FDA approval is real but narrow; the research chemical sold outside that approval is a different object, with none of the regulatory oversight that shaped the trial data ^[2][7]. Alongside MOTS-c, which acts on the metabolic machinery within cells, and CJC-1295, a longer-acting GHRH analogue without any approved use, tesamorelin shows what a well-characterized pituitary stimulator looks like when it reaches the clinic — and what it cannot yet claim beyond that clinic.